advanceCOR GmbH


    • Company type:
      • Research & Development
    • Year founded:
    • 2012
    • Employees (at the site):
    • 25
    • Turnover range:
    • not available
    • Products/services:
    • advanceCOR is a clinical drug developing company, focusing on novel therapeutics and diagnostics for the treatment of heart and vascular diseases. The focus is on the personalized treatment of cardiovascular diseases with large unmet medical need. We provide truly innovative treatments with a companion diagnostic. advanceCOR´s activities and experiences comprise all steps from research to clinical drug development and commercialization.

      One project (Revacept) is in the phase II study at different university hospitals. One project is in the preclinical phase (COR-2) and others in the scientific test stage (COR-3).

      advanceCOR carries out GLP-certified measurements of substances in buffer and serum for preclinical and clinical drug development.

      advanceCOR has also received a good manufacturing practice (GMP) certificate to carry out analytical studies, and has been granted the status of a drug manufacturer.

    • Core competencies:
    • not available

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72: Scientific research and development
      • 72.1: Research and experimental development on natural sciences and engineering
      • 72.11: Research and experimental development on biotechnology
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Prof. Dr. Götz Münch (Mr.)
      - Management

      Prof. Dr. Martin Ungerer (Mr.)
      - Management